USC Oncologia Medica, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy.
Future Oncol. 2014 Feb;10(2):233-9. doi: 10.2217/fon.13.251.
The aim of this study is to report on the activity and safety of eribulin mesylate in a representative number of pretreated metastatic breast cancer (MBC) patients in current practice. Eribulin mesylate, a new microtubule inhibitor, is approved as monotherapy for the treatment of patients with locally advanced breast cancer or MBC who have progressed after at least two chemotherapeutic regimens for advanced disease.
PATIENTS & METHODS: From February to October 2012, 27 MBC patients, previously treated with anthracyclines and taxanes, were treated with 1.4 mg/m(2) intravenous infusion of eribulin mesylate at a community hospital.
Eight (30%) patients achieved partial response, one achieved complete response and three achieved stable disease. Median duration of response was 2.5 months (95% CI: 1.6-5.7; range: 1.3-5.7). Median overall survival was 8 months (95% CI: 6.1-9.7; range: 0.6-9.9). Reported adverse events were grade 1-2 asthenia (83%), peripheral sensory neuropathy (48%), nausea (37%) and neutropenia (30%).
Our retrospective analysis of a clinical practice experience supports the evidence that eribulin mesylate has clinical activity and provides acceptable benefit to heavily pretreated MBC.
本研究旨在报告在当前实践中为数众多的预处理转移性乳腺癌（MBC）患者中，甲磺酸艾瑞布林的活性和安全性。甲磺酸艾瑞布林是一种新型微管抑制剂，被批准用于治疗至少接受过两种晚期疾病化疗方案治疗后进展的局部晚期或 MBC 患者。
2012 年 2 月至 10 月，27 例先前接受过蒽环类和紫杉类药物治疗的 MBC 患者在一家社区医院接受了 1.4mg/m²的艾日布林静脉输注治疗。
8 例（30%）患者获得部分缓解，1 例获得完全缓解，3 例获得稳定疾病。缓解持续时间的中位数为 2.5 个月（95%CI：1.6-5.7；范围：1.3-5.7）。总生存中位数为 8 个月（95%CI：6.1-9.7；范围：0.6-9.9）。报告的不良事件为 1-2 级乏力（83%）、周围感觉神经病变（48%）、恶心（37%）和中性粒细胞减少症（30%）。
我们对临床实践经验的回顾性分析支持这样的证据，即甲磺酸艾瑞布林具有临床活性，并为接受过多重预处理的 MBC 患者提供了可接受的获益。
